Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4049-4058

  Findlay, Brandon ^a   Zhanel, George G ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; ANTIMICROBIAL CATIONIC PEPTIDE; ARGINYLTRYPTOPHYLARGINYLTRYPTOPHYLARGINYLTRYPTOPHANAMIDE; ARGINYLTRYPTOPHYLARGINYLTRYPTOPHYLARGINYLTRYPTOPHYLARGINYLTRYPTOPHYLARGINYLTRYPTOPHANAMIDE; BUFORIN 2; D V 681 V 13K PEPTIDE; LIPOPEPTIDE; MAGAININ 2; MELITTIN; MELLITIN PEPTOID F; PENETRATIN; PLECTASIN; PROTEINASE; RTA F4W PEPTIDE; RTA PEPTIDE; TRYPTOPHYLARGINYLTRYPTOPHAN ESTER; TRYPTOPHYLARGINYLTRYPTOPHANAMIDE; UNCLASSIFIED DRUG; V 681 PEPTIDE; V 681 V 13K PEPTIDE; VANCOMYCIN;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACILLUS SUBTILIS; BACTERICIDAL ACTIVITY; BACTERIUM; CELL MEMBRANE; COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; ENZYME DEGRADATION; ESCHERICHIA COLI; FUNGICIDAL ACTIVITY; HEMOLYSIS; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; INFECTION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TOXICITY;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; HEMOLYSIS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE-ACTIVE AGENTS;

EID: 77957329669     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00530-10     Document Type: Short Survey

References (83)

1. Al-Badri, Z. M., A. Som, S. Lyon, C. F. Nelson, K. Nusslein, and G. N. Tew. 2008. Investigating the effect of increasing charge density on the hemolytic activity of synthetic antimicrobial polymers. Biomacromolecules 9:2805-2810. doi:10.1021/bm800569x.
2. Avrahami, D., and Y. Shai. 2002. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry (NY) 41:2254-2263. doi:10.1021/bi011549t. (Pubitemid 34160886)
3. Baussanne, I., A. Bussiere, S. Halder, C. Ganem-Elbaz, M. Ouberai, M. Riou, J. M. Paris, E. Ennifar, M. P. Mingeot-Leclercq, and J. L. Decout. 2010. Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. J. Med. Chem. 53:119-127. doi:10.1021/jm900615h.
4. Beckloff, N., D. Laube, T. Castro, D. Furgang, S. Park, D. Perlin, D. Clements, H. Tang, R. W. Scott, G. N. Tew, and G. Diamond. 2007. Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob. Agents Chemother. 51:4125-4132. doi:10.1128/AAC.00208-07.
5. Bera, S., G. G. Zhanel, and F. Schweizer. 2008. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity. J. Med. Chem. 51:6160-6164. doi:10.1021/ jm800345u.
6. Bera, S., G. G. Zhanel, and F. Schweizer. 2010. Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. J. Med. Chem. doi:10.1021/jm1000437.
7. Bera, S., G. G. Zhanel, and F. Schweizer. 2010. Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. J. Antimicrob. Chemother. doi:10.1093/jac/dkq083.
8. Bera, S., G. G. Zhanel, and F. Schweizer. 2010. Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorg. Med. Chem. Lett. 20:3031-3035.
9. Bhunia, A., A. Ramamoorthy, and S. Bhattacharjya. 2009. Helical hairpin structure of a potent antimicrobial peptide MSI-594 in lipopolysaccharide micelles by NMR spectroscopy. Chem. Eur. J. 15:2036-2040. doi:10.1002/chem. 200802635.
10. Braunstein, A., N. Papo, and Y. Shai. 2004. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob. Agents Chemother. 48:3127-3129. doi:10.1128/AAC.48.8.3127-3129.2004.
11. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. doi:10.1038/nrmicro1098.
12. Chen, Y., M. T. Guarnieri, A. I. Vasil, M. L. Vasil, C. T. Mant, and R. S. Hodges. 2007. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob. Agents Chemother. 51:1398-1406. doi:10.1128/AAC.00925-06.
13. Chen, Y., C. T. Mant, S. W. Farmer, R. E. Hancock, M. L. Vasil, and R. S. Hodges. 2005. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 280:12316-12329. doi:10.1074/jbc.M413406200.
14. Chen, Y., A. I. Vasil, L. Rehaume, C. T. Mant, J. L. Burns, M. L. Vasil, R. E. Hancock, and R. S. Hodges. 2006. Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem. Biol. Drug Des. 67:162-173. doi:10.1111/j.1747-0285.2006.00349.x.
15. Choi, S., A. Isaacs, D. Clements, D. Liu, H. Kim, R. W. Scott, J. D. Winkler, and W. F. DeGrado. 2009. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U. S. A. 106:6968-6973. doi:10.1073/pnas.0811818106.
16. Chongsiriwatana, N. P., and A. E. Barron. 2010. Comparing bacterial membrane interactions of antimicrobial peptides and their mimics. Methods Mol. Biol. 618:171-182. doi:10.1007/978-1-60761-594-1-12.
17. Dathe, M., and T. Wieprecht. 1999. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1462:71-87. doi:10.1016/S0005- 2736(99)00201-1.
18. Ellerby, H. M., D. E. Bredesen, S. Fujimura, and V. John. 2008. Hunterkiller peptide (HKP) for targeted therapy. J. Med. Chem. 51:5887-5892. doi:10.1021/jm800495u.
19. Fjell, C. D., H. Jenssen, K. Hilpert, W. A. Cheung, N. Pante, R. E. Hancock, and A. Cherkasov. 2009. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J. Med. Chem. 52:2006-2015. doi:10.1021/jm8015365.
20. Flemming, K., C. Klingenberg, J. P. Cavanagh, M. Sletteng, W. Stensen, J. S. Svendsen, and T. Flaegstad. 2009. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J. Antimicrob. Chemother. 63:136-145. doi:10.1093/jac/dkn464.
21. Gabriel, G. J., A. E. Madkour, J. M. Dabkowski, C. F. Nelson, K. Nusslein, and G. N. Tew. 2008. Synthetic mimic of antimicrobial peptide with nonmembrane- disrupting antibacterial properties. Biomacromolecules 9:2980-2983. doi:10.1021/bm800855t.
22. Ge, Y., D. L. MacDonald, K. J. Holroyd, C. Thornsberry, H. Wexler, and M. Zasloff. 1999. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43:782-788.
23. Giménez, D., C. Andreu, M. D. Olmo, T. Varea, D. Diaz, and G. Asensio. 2006. The introduction of fluorine atoms or trifluoromethyl groups in short cationic peptides enhances their antimicrobial activity. Bioorg. Med. Chem. 14:6971-6978. doi:10.1016/j.bmc.2006.06.027.
24. Giuliani, A., G. Pirri, and A. C. Rinaldi. 2010. Antimicrobial peptides: the LPS connection. Methods Mol. Biol. 618:137-154. doi:10.1007/978-1-60761-594- 1-10.
25. Hale, J. D., and R. E. Hancock. 2007. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 5:951-959. doi:10.1586/14787210.5.6.951.
26. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. doi:10.1038/nbt1267.
27. Hancock, R. E., and M. G. Scott. 2000. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U. S. A. 97:8856-8861. doi:10.1073/pnas.97.16.8856.
28. Hansel, W., C. Leuschner, and F. Enright. 2007. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol. Cell. Endocrinol. 269:26-33. doi:10.1016/j.mce.2006.06.017.
29. Haug, B. E., W. Stensen, M. Kalaaji, O. Rekdal, and J. S. Svendsen. 2008. Synthetic antimicrobial peptidomimetics with therapeutic potential. J. Med. Chem. 51:4306-4314. doi:10.1021/jm701600a.
30. Hawrani, A., R. A. Howe, T. R. Walsh, and C. E. Dempsey. 2008. Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. J. Biol. Chem. 283:18636-18645. doi:10.1074/jbc.M709154200.
31. Hilpert, K., R. Volkmer-Engert, T. Walter, and R. E. Hancock. 2005. Highthroughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 23:1008-1012. doi:10.1038/nbt1113.
32. Jadhav, V., S. Maiti, A. Dasgupta, P. K. Das, R. S. Dias, M. G. Miguel, and B. Lindman. 2008. Effect of the head-group geometry of amino acid-based cationic surfactants on interaction with plasmid DNA. Biomacromolecules 9:1852-1859. doi:10.1021/bm8000765.
33. Jenssen, H., P. Hamill, and R. E. Hancock. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511. doi:10.1128/CMR.00056-05.
34. Jiang, Z., A. I. Vasil, J. D. Hale, R. E. Hancock, M. L. Vasil, and R. S. Hodges. 2008. Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides. Biopolymers 90:369-383. doi:10.1002/bip.20911.
35. Klocek, G., T. Schulthess, Y. Shai, and J. Seelig. 2009. Thermodynamics of melittin binding to lipid bilayers. Aggregation/pore formation. Biochemistry 48:2586-2596. doi:10.1021/bi802127h.
36. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132. doi:10.1016/0022-2836(82)90515-0.
37. Liu, Z., A. Brady, A. Young, B. Rasimick, K. Chen, C. Zhou, and N. R. Kallenbach. 2007. Length effects in antimicrobial peptides of the (RW)n series. Antimicrob. Agents Chemother. 51:597-603. doi:10.1128/AAC.00828-06.
38. Liu, Z., A. W. Young, P. Hu, A. J. Rice, C. Zhou, Y. Zhang, and N. R. Kallenbach. 2007. Tuning the membrane selectivity of antimicrobial peptides by using multivalent design. Chembiochem 8:2063-2065. doi:10.1002/cbic.200700502.
39. Madkour, A. E., J. M. Dabkowski, K. Nusslein, and G. N. Tew. 2009. Fast disinfecting antimicrobial surfaces. Langmuir 25:1060-1067. doi:10.1021/ la802953v.
40. Makovitzki, A., J. Baram, and Y. Shai. 2008. Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47:10630-10636. doi:10.1021/bi8011675.
41. Makovitzki, A., and Y. Shai. 2005. pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry 44:9775-9784. doi:10.1021/bi0502386. (Pubitemid 40994371)
42. Malina, A., and Y. Shai. 2005. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem. J. 390:695-702. doi:10.1042/BJ20050520.
43. Marr, A. K., W. J. Gooderham, and R. E. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6:468-472. doi:10.1016/j.coph.2006.04.006.
44. Matsuzaki, K. 2008. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta Biomembr. 1788:1687-1692. doi:10.1016/j.bbamem. 2008.09.013.
45. Melo, M. N., R. Ferre, and M. A. Castanho. 2009. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat. Rev. Microbiol. 7:245-250. doi:10.1038/nrmicro2095.
46. Meng, H., and K. Kumar. 2007. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J. Am. Chem. Soc. 129:15615-15622. doi:10.1021/ja075373f.
47. Mitra, R. N., A. Shome, P. Paul, and P. K. Das. 2009. Antimicrobial activity, biocompatibility and hydrogelation ability of dipeptide-based amphiphiles. Org. Biomol. Chem. 7:94-102. doi:10.1039/b815368j.
48. Mowery, B. P., S. E. Lee, D. A. Kissounko, R. F. Epand, R. M. Epand, B. Weisblum, S. S. Stahl, and S. H. Gellman. 2007. Mimicry of antimicrobial host-defense peptides by random copolymers. J. Am. Chem. Soc. 129:15474-15476. doi:10.1021/ja077288d.
49. Mulvey, M. R., and A. E. Simor. 2009. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 180:408-415. doi:10.1503/cmaj. 080239.
50. Naarmann, N., B. Bilgicer, H. Meng, K. Kumar, and C. Steinem. 2006. Fluorinated interfaces drive self-association of transmembrane alpha helices in lipid bilayers. Angew. Chem. Int. Ed. Engl. 45:2588-2591. doi:10.1002/anie. 200503567.
51. Otter, J. A., and G. L. French. 2006. Nosocomial transmission of communityassociated methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 6:753-755. doi:10.1016/S1473-3099(06)70636-3.
52. Papo, N., and Y. Shai. 2004. Effect of drastic sequence alteration and Damino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry 43:6393-6403. doi:10.1021/bi049944h.
53. Park, C. B., H. S. Kim, and S. C. Kim. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244:253-257. doi:10.1006/bbrc.1998.8159.
54. Perron, G. G., M. Zasloff, and G. Bell. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc. Biol. Sci. 273:251-256. doi:10.1098/rspb.2005.3301.
55. Peschel, A., and H. G. Sahl. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4:529-536. doi:10.1038/nrmicro1441.
56. Putsep, K., G. Carlsson, H. G. Boman, and M. Andersson. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360:1144-1149. doi:10.1016/S0140-6736(02)11201-3. (Pubitemid 35246490)
57. Radzishevsky, I. S., T. Kovachi, Y. Porat, L. Ziserman, F. Zaknoon, D. Danino, and A. Mor. 2008. Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15:354-362. doi:10.1016/j.chembiol.2008.03. 006.
58. Radzishevsky, I. S., S. Rotem, D. Bourdetsky, S. Navon-Venezia, Y. Carmeli, and A. Mor. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25:657-659. doi:10.1038/nbt1309.
59. Rotem, S., and A. Mor. 2009. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788:1582-1592. doi:10.1016/j.bbamem.2008.10.020.
60. Rotem, S., I. S. Radzishevsky, D. Bourdetsky, S. Navon-Venezia, Y. Carmeli, and A. Mor. 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 22:2652-2661. doi:10.1096/fj.07-105015.
61. Sarig, H., S. Rotem, L. Ziserman, D. Danino, and A. Mor. 2008. Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52:4308-4314. doi:10.1128/AAC.00656-08.
62. Schneider, T., T. Kruse, R. Wimmer, I. Wiedemann, V. Sass, U. Pag, A. Jansen, A. K. Nielsen, P. H. Mygind, D. S. Raventos, S. Neve, B. Ravn, A. M. Bonvin, L. De Maria, A. S. Andersen, L. K. Gammelgaard, H. G. Sahl, and H. H. Kristensen. 2010. Plectasin, a fungal defensin, targets the bacterial cell wall precursor lipid II. Science 328:1168-1172. doi:10.1126/science.1185723.
63. Scott, R. W., W. F. DeGrado, and G. N. Tew. 2008. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19:620-627. doi:10.1016/j.copbio.2008.10.013.
64. Serrano, G. N., G. G. Zhanel, and F. Schweizer. 2009. Antibacterial activity of ultrashort cationic lipo-beta-peptides. Antimicrob. Agents Chemother. 53:2215-2217. doi:10.1128/AAC.01100-08.
65. Shai, Y., and Z. Oren. 2001. From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 22:1629-1641. doi:10.1016/S0196-9781(01)00498-3.
66. Song, J. 2008. What's new on the antimicrobial horizon? Int. J. Antimicrob. Agents 32:S207-S213. doi:10.1016/S0924-8579(09)70004-4.
67. Stewart, K. M., K. L. Horton, and S. O. Kelley. 2008. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem. 6:2242-2255. doi:10.1039/b719950c.
68. Strøm, M. B., B. E. Haug, M. L. Skar, W. Stensen, T. Stiberg, and J. S. Svendsen. 2003. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 46:1567. doi:10.1021/jm0340039.
69. Svenson, J., W. Stensen, B. O. Brandsdal, B. E. Haug, J. Monrad, and J. S. Svendsen. 2008. Antimicrobial peptides with stability toward tryptic degradation. Biochemistry 47:3777-3788. doi:10.1021/bi7019904.
70. Tang, H., R. J. Doerksen, T. V. Jones, M. L. Klein, and G. N. Tew. 2006. Biomimetic facially amphiphilic antibacterial oligomers with conformationally stiff backbones. Chem. Biol. 13:427-435. doi:10.1016/j.chembiol.2006.02.007.
71. Tew, G. N., D. Liu, B. Chen, R. J. Doerksen, J. Kaplan, P. J. Carroll, M. L. Klein, and W. F. DeGrado. 2002. De novo design of biomimetic antimicrobial polymers. Proc. Natl. Acad. Sci. U. S. A. 99:5110-5114. doi:10.1073/pnas. 082046199.
72. Vallon-Eberhard, A., A. Makovitzki, A. Beauvais, J. P. Latge, S. Jung, and Y. Shai. 2008. Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys. Antimicrob. Agents Chemother. 52:3118-3126. doi:10.1128/AAC.00526-08.
73. van den Bogaart, G., J. V. Guzman, J. T. Mika, and B. Poolman. 2008. On the mechanism of pore formation by melittin. J. Biol. Chem. 283:33854-33857. doi:10.1074/jbc.M805171200.
74. Wang, G., X. Li, and Z. Wang. 2009. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37:D933-D937. doi:10.1093/nar/gkn823.
75. Wehkamp, J., and E. F. Stange. 2006. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. Ann. N. Y. Acad. Sci. 1072:321-331. doi:10.1196/annals.1326.030.
76. Willcox, M. D., E. B. Hume, Y. Aliwarga, N. Kumar, and N. Cole. 2008. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J. Appl. Microbiol. 105:1817-1825. doi:10.1111/j.1365-2672.2008. 03942.x.
77. Yang, L., V. D. Gordon, D. R. Trinkle, N. W. Schmidt, M. A. Davis, C. DeVries, A. Som, J. E. Cronan, Jr., G. N. Tew, and G. C. Wong. 2008. Mechanism of a prototypical synthetic membrane-active antimicrobial: efficient hole-punching via interaction with negative intrinsic curvature lipids. Proc. Natl. Acad. Sci. U. S. A. 105:20595-20600. doi:10.1073/pnas.0806456105.
78. Zasloff, M. 2002. Antimicrobial peptides in health and disease. N. Engl. J. Med. 347:1199-1200. doi:10.1056/NEJMe020106.
79. Zhang, J., F. I. Chiang, L. Wu, P. G. Czyryca, D. Li, and C. W. Chang. 2008. Surprising alteration of antibacterial activity of 5″-modified neomycin against resistant bacteria. J. Med. Chem. 51:7563-7573. doi:10.1021/jm800997s.
80. Zhang, J., K. Keller, J. Y. Takemoto, M. Bensaci, A. Litke, P. G. Czyryca, and C. W. Chang. 2009. Synthesis and combinational antibacterial study of 5″-modified neomycin. J. Antibiot. (Tokyo) 62:539-544. doi:10.1038/ja.2009.66.
81. Zhu, W. L., H. Lan, I. S. Park, J. I. Kim, H. Z. Jin, K. S. Hahm, and S. Y. Shin. 2006. Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. Biochem. Biophys. Res. Commun. 349:769-774. doi:10.1016/j.bbrc.2006.08.094.
82. Zhu, W. L., and S. Y. Shin. 2009. Antimicrobial and cytolytic activities and plausible mode of bactericidal action of the cell penetrating peptide penetratin and its lys-linked two-stranded peptide. Chem. Biol. Drug Des. 73:209-215. doi:10.1111/j.1747-0285.2008.00769.x.
83. Zhu, W. L., Y. M. Song, Y. Park, K. H. Park, S. T. Yang, J. I. Kim, I. S. Park, K. S. Hahm, and S. Y. Shin. 2007. Substitution of the leucine zipper sequence in melittin with peptoid residues affects self-association, cell selectivity, and mode of action. Biochim. Biophys. Acta 1768:1506-1517. doi:10.1016/j.bbamem.2007.03.010.